Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Current Position of Merck & Co Currently trading with a volume of 12,034,764, the MRK's price is up by 1.57%, now at $74.62. RSI readings suggest the stock is currently is currently neutral ...

Summary >40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value.

Merck & Co. shows strong financial health, indicating long-term stability. Despite recent earnings volatility, Merck's 5-year average ROE of 28.3% and gross margin percent of 70.68% highlight its ...

Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese biopharmaceutical company Hansoh Pharma.

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...

We recently compiled a list titled 7 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. In this article, we will look at where Merck & Co., Inc.

Financial giants have made a conspicuous bullish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE:MRK) revealed 9 unusual trades.Delving into the details, we found 55% of ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday. The company’s shares closed yesterday at $128.71. Hellweg covers the ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.The fund advanced 8.92% ...

Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. has pushed further into the space by penning a $220 million biobucks deal with Unnatural Products.